GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » Book Value per Share

Intec Parent (Intec Parent) Book Value per Share : $10.08 (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Intec Parent Book Value per Share?

Intec Parent's book value per share for the quarter that ended in Mar. 2021 was $10.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Intec Parent's current price is $9.63. Its book value per share for the quarter that ended in Mar. 2021 was $10.08. Hence, today's PB Ratio of Intec Parent is 0.96.


Intec Parent Book Value per Share Historical Data

The historical data trend for Intec Parent's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Book Value per Share Chart

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Book Value per Share
Get a 7-Day Free Trial 158.66 180.40 128.90 25.47 13.45

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.48 18.64 18.31 13.45 10.08

Competitive Comparison of Intec Parent's Book Value per Share

For the Biotechnology subindustry, Intec Parent's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Parent's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Parent's PB Ratio distribution charts can be found below:

* The bar in red indicates where Intec Parent's PB Ratio falls into.



Intec Parent Book Value per Share Calculation

Intec Parent's Book Value Per Share for the fiscal year that ended in Dec. 2020 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14.53-0.00)/1.08
=13.45

Intec Parent's Book Value Per Share for the quarter that ended in Mar. 2021 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(11.34-0.00)/1.13
=10.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Intec Parent  (NAS:NTEC) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Intec Parent Book Value per Share Related Terms

Thank you for viewing the detailed overview of Intec Parent's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent (Intec Parent) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco director 7 HAORANIM STREET BAZRA L3 60944